Quick Listen: Scrip's Five Must-Know Things
Executive Summary
In this week's podcast edition of Five Must-Know Things: the shifting sands of pharma R&D; big pharma oncology strategies; semaglutide’s promise in heart failure; AstraZeneca looks to multiple cancer modalities; and an interview with Astellas’s chief strategy officer.
Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 12 April 2024, including: the shifting sands of pharma R&D; big pharma oncology strategies; semaglutide’s promise in heart failure; AstraZeneca PLC looks to multiple cancer modalities; and an interview with Astellas Pharma, Inc.’s chief strategy officer.
This and all our other podcasts are available on the Citeline channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode:
(Also see "The Shifting Sands Of Biopharma R&D" - Scrip, 8 Apr, 2024.)
(Also see "Big Pharma Oncology Strategies Aim To Treat Cancer Earlier" - Scrip, 9 Apr, 2024.)
(Also see "Semaglutide Might Treat Heart Failure Directly" - Scrip, 8 Apr, 2024.)
(Also see "AstraZeneca Looks To Many Modalities In Cancer" - Scrip, 8 Apr, 2024.)
(Also see "Astellas CStO Pearson: We’re Not Short Of Opportunities To Compensate For LOEs" - Scrip, 8 Apr, 2024.)